Steve Debenport /
16 July 2018Americas

LSIPR 50 2018: An agent of change in healthcare

Managing around $8 billion in funds, Deerfield is a big player in the healthcare investment field. The firm focuses on every area of healthcare (including healthcare services, medical devices, pharmaceuticals and biotech) at every stage of development, from funding academic research before it’s been spun out through to public markets. At any one point in time, Illinois-based Deerfield has approximately 300 investments.

While these are impressive statistics, this is not the only reason James Flynn was selected for LSIPR 50. His role in making Deerfield an “important agent of change in advancing healthcare” merited his inclusion in the list.

Flynn joined Deerfield in 2000, at a time when it was operating as a public equity trading firm. Since then, he’s been on a mission to make Deerfield important to human health by creating infrastructure and activities to fill in social gaps where the company sees them.

The Deerfield Foundation, which has invested and committed over $30 million in its partner projects, is predominantly focused on children’s healthcare issues.

The foundation, which is managed by a rotating group of eight employees, approaches funding in a similar way to Deerfield’s approach to investments, ie, measuring the impact of the investments.

“If we can’t measure the impact or things don’t progress the way they should then we stop funding in that area. But if they do improve, we increase funding,” Flynn explains.

Work in progress

The foundation has invested in healthcare clinics in New York City, and obstetric clinics in Haiti, and has funded mobile medical units for homeless children.

There have been some very long-term partnerships (such as the Children’s Health Fund and Partners in Health) which, according to Flynn, have “done a phenomenal job” of creating the types of services and change that the company hoped to see.

Funds for the foundation are provided through partner contributions and directly from Deerfield’s profits. All the profits from Deerfield’s Healthcare Innovation Fund, which is focused on very early seed and series A investments, go into the foundation.

Completing the trio is the Deerfield Institute, the research base. It consists of 40 information specialists: epidemiologists who focus on patient populations, IP lawyers and people who focus on survey research.

“It’s often the case that patient populations in literature are described incorrectly,” notes Flynn. For example, he says, if a patient advocacy group is describing the patient population, then everyone has the disease. But if a drug company is going to launch in Europe for instance, then it will describe no-one as having the disease there as typically the price of a drug rises with the fewer people who have the disease.

When the institute discovers a patient population to be incorrect, it publishes an article on that topic. Since 2015, Deerfield has published more than 40 articles, reviews and abstracts.


In October 2017, Deerfield announced a collaboration with the Broad Institute of MIT and Harvard, aimed at “advancing therapeutics by funding promising early-stage research”.

In February this year, the partnership announced the advancement of two projects to focus on novel targets that reveal underlying vulnerabilities in acute leukaemia and common genetic alterations in cancer. The partnership may start on a third target shortly.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at